Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT1A receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain

Psychopharmacology

Volumn 231, Issue 20, 2014, Pages 3973-3985

  Liu, Yuan Yuan ^a   Yin, Dou ^a   Chen, Li ^a   Qu, Wei Min ^a   Chen, Chang Rui ^a   Laudon, Moshe ^b   Cheng, Neng Neng ^a   Urade, Yoshihiro ^c   Huang, Zhi Li ^a  

^a FUDAN UNIVERSITY   (China)

^b NEURIM PHARMACEUTICALS LTD   (Israel)

^c OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Insomnia; Luzindole; Naloxone; Neuropathic pain; Piromelatine; WAY 100635

Indexed keywords

ANALGESIC AGENT; HYPNOTIC SEDATIVE AGENT; INDOLE DERIVATIVE; LUZINDOLE; MELATONIN; MELATONIN RECEPTOR; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; N-(2-(5-METHOXY-INDOL-3-YL)-ETHYL)-4-OXO-4H-PYRAN-2-CARBOXAMIDE; NALOXONE; NARCOTIC ANTAGONIST; OPIATE RECEPTOR; PIPERAZINE DERIVATIVE; PYRAN DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN ANTAGONIST; TRYPTAMINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; HYPERALGESIA; INJURIES; MALE; METABOLISM; MOUSE; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVE INJURY; SCIATIC NERVE; SLEEP DISORDERS;

ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; HYPERALGESIA; HYPNOTICS AND SEDATIVES; INDOLES; MALE; MELATONIN; MICE; NALOXONE; NARCOTIC ANTAGONISTS; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVE INJURIES; PIPERAZINES; PYRANS; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, MELATONIN; RECEPTORS, OPIOID; SCIATIC NERVE; SEROTONIN ANTAGONISTS; SLEEP DISORDERS; TRYPTAMINES;

EID: 84897348935     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3530-5     Document Type: Article

References (53)

1. Ambriz-Tututi M, Granados-Soto V (2007) Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 132:273-280
2. Anjaneyulu M, Chopra K (2006) Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice. Eur J Pharmacol 538:80-84
3. Argoff CE (2007) The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 23:15-22
4. Barros TA, de Freitas LA, Filho JM, Nunes XP, Giulietti AM, de Souza GE, dos Santos RR, Soares MB, Villarreal CF (2010) Antinociceptive and anti-inflammatory properties of 7-hydroxycoumarin in experimental animal models: potential therapeutic for the control of inflammatory chronic pain. J Pharm Pharmacol 62:205-213
5. Blagestad T, Pallesen S, Lunde LH, Sivertsen B, Nordhus IH, Gronli J (2012) Sleep in older chronic pain patients: a comparative polysomnographic study. Clin J Pain 28:277-283
6. Browning C, Beresford I, Fraser N, Giles H (2000) Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 129:877-886
7. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41-50
8. Comai S, Ochoa-Sanchez R, Gobbi G (2013) Sleep-wake characterization of double MT(1)/MT(2) receptor knockout mice and comparison with MT(1) and MT(2) receptor knockout mice. Behav Brain Res 243:231-238
9. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462
10. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI (1998) Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 12:1211-1220
11. Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E (2005) Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res 39:113-120
12. Fisher SP, Davidson K, Kulla A, Sugden D (2008) Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat. J Pineal Res 45:125-132
13. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic, San Diego
14. Gomez-Corvera A, Cerrillo I, Molinero P, Naranjo MC, Lardone PJ, Sanchez-Hidalgo M, Carrascosa-Salmoral MP, Medrano-Campillo P, Guerrero JM, Rubio A (2009) Evidence of immune system melatonin production by two pineal melatonin deficient mice, C57BL/6 and Swiss strains. J Pineal Res 47:15-22
15. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88
16. Huang ZL, Mochizuki T, Qu WM, Hong ZY, Watanabe T, Urade Y, Hayaishi O (2006) Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc Natl Acad Sci U S A 103:4687-4692
17. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR (2003) Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 23:1054-1060
18. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48:301-310
19. Kuribara H, Higuchi Y, Tadokoro S (1977) Effects of central depressants on rota-rod and traction performances in mice. Jpn J Pharmacol 27:117-126
20. Lakin ML, Miller CH, Stott ML, Winters WD (1981) Involvement of the pineal gland and melatonin in murine analgesia. Life Sci 29:2543-2551
21. Laudon M, Peleg-Shulman T (2009) Pyrone-indole derivatives and process for their preparation. Patent US 7635710 B2
22. Laudon M, Urade Y, Huang Z (2008) Neu-P11, a novel melatonin agonist: effects on sleep and EEG power spectra in rats. Sleep 31:A34
23. Laudon M, Katz A, Metzger D, Staner L, Pross N, Cornette F, Guichard N, Nir T, Zisapel N (2012) Tolerability, pharmacokinetic and pharmacodynamic evaluation of multiple ascending doses of Neu-P11 in insomnia patients. Sleep 35:A655
24. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM (1997) Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19:91-102
25. Mantovani M, Kaster MP, Pertile R, Calixto JB, Rodrigues AL, Santos AR (2006) Mechanisms involved in the antinociception caused by melatonin in mice. J Pineal Res 41:382-389
26. Mendelson WB (2002) Melatonin microinjection into the medial preoptic area increases sleep in the rat. Life Sci 71:2067-2070
27. Mickle A, Sood M, Zhang Z, Shahmohammadi G, Sengupta JN, Miranda A (2010) Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process. Pain 149:555-564
28. Miyamoto M (2009) Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 15:32-51
29. Monnet FP (2002) Melatonin modulates [3h]serotonin release in the rat hippocampus: effects of circadian rhythm. J Neuroendocrinol 14:194-199
30. Morin AK (2006) Strategies for treating chronic insomnia. Am J Manage Care 12:S230-S245
31. Morin CM, Gibson D, Wade J (1998) Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 14:311-314
32. Narita M, Niikura K, Nanjo-Niikura K, Furuya M, Yamashita A, Saeki M, Matsushima Y, Imai S, Shimizu T, Asato M, Kuzumaki N, Okutsu D, Miyoshi K, Suzuki M, Tsukiyama Y, Konno M, Yomiya K, Matoba M, Suzuki T (2011) Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. Pain 152:1358-1372
33. Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, Rivara S, Bedini A, Angeloni D, Fraschini F, Mor M, Tarzia G, Descarries L, Gobbi G (2011) Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 31:18439-18452
34. Paulis L, Simko F, Laudon M (2012) Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs 21:1661-1678
35. Peles E, Schreiber S, Adelson M (2009) Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. Eur Neuropsychopharmacol 19:581-588
36. Perissin L, Boccalon S, Scaggiante B, Petrelli L, Ortolani F, Porro CA (2004) Diurnal changes of tonic nociceptive responses in mice: evidence for a proalgesic role of melatonin. Pain 110:250-258
37. Shavali S, Ho B, Govitrapong P, Sawlom S, Ajjimaporn A, Klongpanichapak S, Ebadi M (2005) Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res Bull 64:471-479
38. Siuciak JA, Fang JM, Dubocovich ML (1990) Autoradiographic localization of 2-[125I]iodomelatonin binding sites in the brains of C3H/HeN and C57BL/6J strains of mice. Eur J Pharmacol 180:387-390
39. Smith MT, Haythornthwaite JA (2004) How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev 8:119-132
40. Smith MT, Perlis ML, Smith MS, Giles DE, Carmody TP (2000) Sleep quality and presleep arousal in chronic pain. J Behav Med 23:1-13
41. Spadoni G, Bedini A, Rivara S, Mor M (2011) Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 17:733-741
42. Srinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP, Brown GM (2011) Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 35:913-923
43. Takemura Y, Yamashita A, Horiuchi H, Furuya M, Yanase M, Niikura K, Imai S, Hatakeyama N, Kinoshita H, Tsukiyama Y, Senba E, Matoba M, Kuzumaki N, Yamazaki M, Suzuki T, Narita M (2011) Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis. Synapse 65:668-676
44. Tian SW, Laudon M, Han L, Gao J, Huang FL, Yang YF, Deng HF (2010) Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin 31:775-783
45. Ulugol A, Dokmeci D, Guray G, Sapolyo N, Ozyigit F, Tamer M (2006) Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: Possible involvements of the L-arginine-NO pathway and opioid system. Life Sci 78:1592-1597
46. Wang F, Li JC, Wu CF, Yang JY, Zhang RM, Chai HF (2003) Influences of a light-dark profile and the pineal gland on the hypnotic activity of melatonin in mice and rats. J Pharm Pharmacol 55:1307-1312
47. Wang S, Tian Y, Song L, Lim G, Tan Y, You Z, Chen L, Mao J (2012) Exacerbated mechanical hyperalgesia in rats with genetically predisposed depressive behavior: role of melatonin and NMDA receptors. Pain 153:2448-2457
48. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I (2011) Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 51:270-277
49. Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA (2006) Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 29:609-618
50. Xu XH, Qiu MH, Dong H, Qu WM, Urade Y, Huang ZL (2014) GABA transporter-1 inhibitor NO-711 alters the EEG power spectra and enhances non-rapid eye movement sleep during the active phase in mice. Eur Neuropsychopharmacol 24:585-594
51. Yalkinoglu O, Zisapel N, Nir T, Piechatzek R, Schorr-Neufing U, Bitterlich N, Allgaier C, Oertel R, Kluge A, Laudon M (2010) Phase-I study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-P11, a novel putative insomnia drug in healthy humans. Sleep 33:A220
52. Yu CX, Wu GC, Xu SF, Chen CH (2001) Effect of melatonin on release of beta-endorphin, norepinephrine and 5-hydroxytryptamine in rat brain. Yao Xue Xue Bao 36:5-9
53. Zhao X, Xu Y, Zhao Q, Chen CR, Liu AM, Huang ZL (2012) Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are differentially involved. Neuropharmacology 62:843-854